Vyant Bio Issues Letter to Shareholders
March 01, 2022 08:30 ET
|
Vyant Bio, Inc.
Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological...
Parkinson’s Disease Drugs Market to reach USD 8,383.2 Million by 2026 | Market Projection By Technology, Major key players, Growth, Revenue, CAGR, Regional Analysis, Industry Forecast
November 15, 2021 04:08 ET
|
Fortune Business Insights
Pune, India, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The Global Parkinson's Disease Drugs Market is likely to grow in the coming years due to the growing emphasis on the treatment of Parkinson's disease....
Manufacturing Commences on Adhera’s MLR-1019 for Phase 2a Clinical Trial Treating Parkinson’s Disease
October 15, 2021 10:21 ET
|
Adhera Therapeutics, Inc.
IP Estate Grows with New Korean Patent Issued Baton Rouge, LA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage...
Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs
September 13, 2021 10:28 ET
|
Adhera Therapeutics, Inc.
Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an...
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate
July 29, 2021 09:00 ET
|
Adhera Therapeutics, Inc.
Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PDArmesocarb is the active...
IMAC Holdings, Inc. Announces Initiation of Second Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
July 13, 2021 09:00 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, July 13, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has initiated the second cohort of its Phase 1 clinical trial for...
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
June 07, 2021 08:45 ET
|
Adhera Therapeutics, Inc.
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
March 01, 2021 09:25 ET
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for...
Parkinson’s Disease Market Value Anticipated To Reach US$ 4,764.3 Mn By 2027: Acumen Research And Consulting
February 03, 2021 13:44 ET
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Parkinson’s disease Market– Global Industry Analysis, Market Size, Opportunities...
Parkinson’s Disease Therapeutic Market revenue to cross USD 8 Bn by 2027: Global Market Insights, Inc.
January 26, 2021 06:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Jan. 26, 2021 (GLOBE NEWSWIRE) -- According to latest report “Parkinson’s Disease Therapeutic Market by Drug Class (Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A...